JERSEY CITY, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (the Company or

Mr. Subramanian brings more than 20 years of finance, capital markets, business development and oper

Accomplished biopharmaceutical finance executive brings extensive experience driving capital markets

SCYNEXIS, Inc. (NASDAQ: SCYX - Get Free Report) shares crossed above its 50 day moving average durin

JERSEY CITY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stag

Gainers Biohaven (NYSE:BHVN) shares increased by 16.5% to $16.75 during Wednesday's regular ses

JERSEY CITY, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage

Guggenheim analyst Vamil Divan maintains SCYNEXIS (NASDAQ:SCYX) with a Buy and raises the price t

SCYNEXIS (NASDAQ:SCYX) reported quarterly losses of $(0.57) per share which missed the analyst conse

SCYNEXIS (NASDAQ:SCYX) reported quarterly earnings of $0.63 per share which beat the analyst consens

SCYNEXIS, Inc. (NASDAQ: SCYX - Get Free Report) shares passed below its two hundred day moving avera

Gainers Replimune Group (NASDAQ:REPL) stock rose 96.1% to $10.61 during Friday's regular sessio

SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company advancing novel therapies for

JERSEY CITY, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage

(Editor’s note: The future prices of benchmark tracking ETFs, and the headline were updated in the s

U.S. stock futures are up, with investor focus on quarterly earnings from AutoZone, Elbit Systems, S

SCYNEXIS, Inc. (NASDAQ:SCYX) ("SCYNEXIS"), a clinical-stage biotechnology company dedicated

SCYNEXIS's Common Stock to Begin Trading on Post-Split Adjusted Basis on June 1, 2026 SCYNEXIS's Com

SCYNEXIS (NASDAQ:SCYX) reported quarterly losses of $(0.42) per share which missed the analyst conse

JERSEY CITY, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage

JERSEY CITY, N. J. , May 06, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) ("SCYNEXIS" or t

SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Th

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinica

SCYNEXIS, Inc. (NASDAQ: SCYX) ("SCYNEXIS" or the "Company"), a biotechnology company

JERSEY CITY, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:  SCYX ) (“SCYNEXIS” or

SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company focused on developing innovative new therapies

PXL-770 (now SCY-770) is a clinical stage, well-characterized oral therapy designed to address the u

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1123525

SCYNEXIS (NASDAQ:SCYX) reported quarterly earnings of $0.25 per share which beat the analyst consens

JERSEY CITY, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome a

JERSEY CITY, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTC

KalVista Pharmaceuticals (NASDAQ: KALV - Get Free Report) and SCYNEXIS (NASDAQ: SCYX - Get Free Repo

SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome an

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome a

SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome an

JERSEY CITY, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology

GSK remains committed to the relaunch of BREXAFEMME, and following its relaunch, SCYNEXIS stands to

Five-year grant of $7 million annually to the academic researchers is aimed at accelerating the deve

SCYNEXIS (NASDAQ:SCYX) reported quarterly losses of $(0.17) per share which beat the analyst consens

Guggenheim analyst Vamil Divan maintains SCYNEXIS (NASDAQ:SCYX) with a Buy and lowers the price t

SCYNEXIS to receive a $22 million payment as part of the resolution related to the restart of the Ph